WikiMD is the world's largest medical encyclopedia with
13,854 pages, 4,142,505 edits & 40,133,090 views.
ATR kinase inhibitor AZD6738
An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.
Learn more about ATR kinase inhibitor AZD6738
- Dailymed label info
- Scientific articles
- Drug portal ATR kinase inhibitor AZD6738
- toxicity info on ATR kinase inhibitor AZD6738
- FDA ATR kinase inhibitor AZD6738
Latest research - ATR kinase inhibitor AZD6738
External links
This WikiMD article ATR kinase inhibitor AZD6738 is a stub. If you are familiar with the topic ATR kinase inhibitor AZD6738, you can help us. Paid editors welcome!
ATR kinase inhibitor AZD6738 is part of WikiMD's free ^articles!
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
 Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available |
